"Ten patients (20.0% ITT; 23.8% PP) had surgical resection " -Ross P.J, Wasan H.S, Croagh D et. al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy, ESMO Open, 2021, 7(1) https://doi.org/10.1016/j.esmoop.2021.100356.
So a difference of 3.8% for surgical resection, which once again, isn't great and is also possibly a statistical anomaly due to the strength of the sample size (if they ran the study 100 times, I would bet money on it that many of those studies would yield negative results).
I am not saying they did anything wrong by having a small sample size, the truth is, you often get small sample sizes for rare cancer studies.
All I am saying is, if I was big pharma, I wouldn't care in the slightest by a 3.8% increase in surgical resection, or an increase of 0.3month median overall survival. And that is probably why they didn't sell anything, because the studies did not yield compelling evidence.
OSL Price at posting:
4.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)